Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money
This article was originally published in PharmAsia News
Executive Summary
Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.
You may also be interested in...
2022 Korean VC Financings Led By Mid-Stage Bioventures
Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
From Science To Commercialization: How Genexine Is Making The Shift
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.